What is Aperiam Bio?
Founded in 2020, Aperiam Bio occupies a unique niche at the intersection of computational biology and material science. By leveraging advanced 3D computer vision, the company is effectively re-engineering proteins to exhibit superior performance characteristics compared to their naturally occurring counterparts. This technological edge positions Aperiam Bio as a disruptive force in the biopharma landscape, particularly in the development of high-efficacy pulmonary treatments. The company's ability to synthesize data-driven protein design with scalable manufacturing processes marks a significant departure from traditional, trial-and-error biological discovery methods, establishing a new benchmark for efficiency in the life sciences industry.
How much funding has Aperiam Bio raised?
Aperiam Bio has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2023): $9M with participation from KdT Ventures, Axial Worldwide, and Civilization Ventures
Key Investors in Aperiam Bio
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
Axial Worldwide
Axial Worldwide Corporation is a digital solutions provider specializing in website design, development, and SEO strategies for corporate clients.
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions.
What's next for Aperiam Bio?
With this major enterprise-level funding secured, Aperiam Bio is well-positioned to scale its computational infrastructure and expand its laboratory capabilities. The strategic roadmap likely involves deepening its intellectual property portfolio and advancing lead candidates through preclinical validation. By focusing on the fundamental engineering of proteins, the company is poised to address complex respiratory challenges that have historically remained resistant to conventional therapeutic approaches. Investors will be closely monitoring the firm's ability to translate its algorithmic protein improvements into tangible clinical outcomes, a milestone that would significantly enhance its valuation and market influence in the coming fiscal cycles.
See full Aperiam Bio company page
